Heghine Khachatryan: When to Consider Ehlers–Danlos Syndromes in Patients with Bleeding Symptoms?
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared European Association for Haemophilia and Allied Disorders (EAHAD)’s post on LinkedIn, adding:
”When Should We Consider Ehlers–Danlos Syndromes in Patients with Bleeding Symptoms?
Connective tissue disorders, particularly Ehlers–Danlos Syndromes (EDS), remain under-recognized in daily hematology practice — yet they frequently present with hemorrhagic manifestations that may mimic primary hemostatic disorders.
The newly released EAHAD e-learning module (Module 21) provides valuable clinical insight into:
- Recognizing red flags in patients with unexplained bleeding
- Understanding the overlap between connective tissue fragility and hemostatic abnormalities
- Improving multidisciplinary diagnostic pathways
- Avoiding misdiagnosis of inherited bleeding disorders
As clinicians working in benign hematology and hemostasis, it is essential that we broaden our differential diagnosis when laboratory results do not fully explain the clinical phenotype.
Timely identification of EDS can significantly impact patient management, perioperative planning, and long-term follow-up.
I strongly encourage colleagues involved in bleeding disorders, women’s health, and rare disease diagnostics to explore this educational resource.”
Quoting European Association for Haemophilia and Allied Disorders (EAHAD)’s post:
”Don’t miss our e-learning module on the Ehlers-Danlos Syndromes (EDS), rare, inherited multisystemic connective tissue disorders frequently associated with bleeding symptoms and haematological challenges.”
Proceed to the video attached to the post.
Find more posts featuring Heghine Khachatryan on Hemostasis Today.
-
Aug 24, 2026, 18:13Chokri Ben Lamine: Ruxolitinib – Comprehensive Clinical Reference
-
Aug 24, 2026, 18:10Yazan Abou-Ismail: ClotCast Episode 8 – What Are Platelets?
-
Aug 24, 2026, 17:11Kristin Neves: Which Hematologic Parameters Guide Your PV Treatment Decisions?
-
Aug 24, 2026, 17:00Should Hormone Therapy Automatically Stop After a Thrombosis? – Thrombosis Canada
-
Aug 24, 2026, 16:52Davide Capodanno: 10 Trials to Watch at the ESC Hot Lines
-
Aug 24, 2026, 16:48Mohd Ashhad: The Science Behind a Safe Transfusion
-
Aug 24, 2026, 16:38PCSK9i Is a Powerful Lipid-Lowering Strategy – But Is It Also Anti-Inflammatory?- JACC Journals
-
Aug 24, 2026, 16:36Alejandro González Veliz։ Does ACC/AHA Lesion Complexity Still Matter?
-
Aug 24, 2026, 16:21Kamlesh Darji: Paraneoplastic Syndromes – Tumor with or without Mediator